Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, pilot and expansion pharmacodynamic Study of (Z)-endoxifen in Patients with Invasive Breast Cancer Prior to Undergoing Mastectomy or Lumpectomy

Next Previous
Trial Profile

An open label, pilot and expansion pharmacodynamic Study of (Z)-endoxifen in Patients with Invasive Breast Cancer Prior to Undergoing Mastectomy or Lumpectomy

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Endoxifen (Primary)
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Sponsors Atossa Therapeutics

Most Recent Events

  • 09 Jun 2021 Primary endpoint (To assess the effect of pre-operative oral (Z)-Endoxifen treatment on clinical response measured by Ki67 expression levels. Ki67 will be assessed via tumor biopsy analysis.) has been met, according to an Atossa Therapeutics Media Release.
  • 09 Jun 2021 Final results published in an Atossa Therapeutics Media Release.
  • 07 Jun 2021 According to an Atossa Therapeutics media release, the company announces that it will hold a webinar at 8 am Pacific Time on June 9, 2021 to release and discuss final data from this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top